Drug use evaluation of erythropoieting (EPO) in hemodialysis patients of national Taiwan university hospital
碩士 === 國立臺灣大學 === 藥學研究所 === 84 === Chronic renal failure is often associatedwith anemia, primarily due to inability of the failing kidney to synthesize sufficient erythropoietin. Erythropoietin (EPO) is the drug of choice in these patients. Its efficacy is decreased...
Main Authors: | Shen,Li-Jiuan, 沈麗娟 |
---|---|
Other Authors: | Chen,C-S |
Format: | Others |
Language: | zh-TW |
Published: |
1995
|
Online Access: | http://ndltd.ncl.edu.tw/handle/34665008363044242123 |
Similar Items
-
ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury
by: van Rijt Willem G, et al.
Published: (2013-01-01) -
Effect of Ascorbic acid on EPO-hyporesponsive anemia in Hemodialysis patients
by: Jimin Jeon, et al.
Published: (2012-06-01) -
Erythropoietic protoporphyria
by: Puy Hervé, et al.
Published: (2009-09-01) -
Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients
by: Kazuya Takasawa, et al.
Published: (2014-04-01) -
Congenital erythropoietic porphyria
by: Wen-Hao Lee, et al.
Published: (2012-06-01)